Huntington National Bank Purchases 2,986 Shares of Eli Lilly and Company (LLY)

Huntington National Bank lifted its position in shares of Eli Lilly and Company (NYSE:LLY) by 1.6% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 185,381 shares of the company’s stock after acquiring an additional 2,986 shares during the quarter. Huntington National Bank’s holdings in Eli Lilly and were worth $15,857,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Pathstone Family Office LLC increased its holdings in Eli Lilly and by 100.0% in the second quarter. Pathstone Family Office LLC now owns 58 shares of the company’s stock valued at $4,774,000 after purchasing an additional 29 shares during the last quarter. Vantage Financial Partners Ltd. Inc. bought a new stake in Eli Lilly and in the second quarter valued at about $494,000. Acrospire Investment Management LLC increased its holdings in Eli Lilly and by 16.7% in the second quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock valued at $115,000 after purchasing an additional 200 shares during the last quarter. MPS Loria Financial Planners LLC bought a new stake in Eli Lilly and in the second quarter valued at about $128,000. Finally, San Francisco Sentry Investment Group CA bought a new stake in Eli Lilly and in the second quarter valued at about $129,000. Institutional investors own 76.43% of the company’s stock.

In other news, SVP Alfonso G. Zulueta sold 2,003 shares of the company’s stock in a transaction dated Friday, November 10th. The stock was sold at an average price of $83.67, for a total transaction of $167,591.01. Following the completion of the transaction, the senior vice president now directly owns 43,580 shares of the company’s stock, valued at $3,646,338.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Susan Mahony sold 36,585 shares of the company’s stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $86.18, for a total value of $3,152,895.30. Following the transaction, the senior vice president now directly owns 54,885 shares of the company’s stock, valued at $4,729,989.30. The disclosure for this sale can be found here. Insiders have sold 628,588 shares of company stock valued at $53,399,536 over the last ninety days. 0.20% of the stock is owned by insiders.

Eli Lilly and Company (LLY) traded up $0.48 during trading hours on Wednesday, reaching $86.06. The company’s stock had a trading volume of 3,876,700 shares, compared to its average volume of 3,672,667. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 0.66. The firm has a market capitalization of $94,231.72, a PE ratio of 20.92, a price-to-earnings-growth ratio of 1.88 and a beta of 0.35. Eli Lilly and Company has a 1 year low of $66.39 and a 1 year high of $89.09.

Eli Lilly and (NYSE:LLY) last posted its quarterly earnings data on Tuesday, October 24th. The company reported $1.05 earnings per share for the quarter, topping the consensus estimate of $1.03 by $0.02. The company had revenue of $5.66 billion during the quarter, compared to analysts’ expectations of $5.52 billion. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. Eli Lilly and’s revenue for the quarter was up 9.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.88 earnings per share. equities analysts expect that Eli Lilly and Company will post 4.21 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 8th. Stockholders of record on Wednesday, November 15th will be given a dividend of $0.52 per share. The ex-dividend date is Tuesday, November 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.42%. Eli Lilly and’s dividend payout ratio is currently 98.58%.

A number of equities research analysts recently commented on LLY shares. BMO Capital Markets reiterated a “sell” rating and issued a $73.00 price objective on shares of Eli Lilly and in a report on Wednesday, August 16th. BidaskClub downgraded Eli Lilly and from a “hold” rating to a “sell” rating in a report on Tuesday, August 22nd. Jefferies Group reiterated a “buy” rating and issued a $89.00 price objective (down previously from $94.00) on shares of Eli Lilly and in a report on Thursday, August 24th. Leerink Swann reissued a “hold” rating on shares of Eli Lilly and in a research note on Thursday, August 31st. Finally, Piper Jaffray Companies reissued a “buy” rating and issued a $103.00 target price on shares of Eli Lilly and in a research note on Thursday, August 31st. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating and nine have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $90.25.

TRADEMARK VIOLATION NOTICE: This article was first published by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this article on another publication, it was illegally stolen and republished in violation of US and international trademark and copyright legislation. The original version of this article can be viewed at https://stocknewstimes.com/2017/12/06/huntington-national-bank-purchases-2986-shares-of-eli-lilly-and-company-lly.html.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply